Short-term and long-term safety of glucocorticoids in rheumatoid arthritis

Bulletin of the NYU Hospital for Joint Diseases

Volumn 70, Issue SUPPL. 1, 2012, Pages

  Saag, Kenneth G ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TRIAMCINOLONE;

ACNE; ADRENAL SUPPRESSION; AKATHISIA; ARTICLE; BONE DENSITY; BONE NECROSIS; BONE REMODELING; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DEPRESSION; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; ECCHYMOSIS; FLUID RETENTION; FRACTURE; GASTRITIS; GLAUCOMA; HIRSUTISM; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; INTESTINAL BLEEDING; INTESTINE ULCER; LIPID BLOOD LEVEL; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORTALITY; MYOCARDIAL DISEASE; MYOPATHY; OSTEOLYSIS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; SODIUM RETENTION; STRIA; SYSTEMATIC REVIEW (TOPIC);

ARTHRITIS, RHEUMATOID; GLUCOCORTICOIDS; HUMANS; PATIENT SAFETY; TREATMENT OUTCOME;

EID: 84872785910     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Da Silva JAP, Jacobs JWG, Kirwan JR, et al. Low-dose glucocorticoid therapy in rheumatoid arthritis. A review on safety: published evidence and prospective trial data. Ann Rheum Dis. 2006 Mar;65(3):285-293. Epub 2005 Aug 17.
2. van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010 Nov;69(11):1913-1919. Epub 2010 Aug 6.
3. McDougall R, Sibley J, Haga M, Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheum. 1994 Jul;21(7):1207-1213.
4. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994 Feb;96(2):115-123.
5. Wolfe F, Furst D, Lane N, et al. Substantial increases in important adverse events follow low dose prednisone therapy of rheumatoid arthritis (RA). Arthritis Rheum. 1995;38:S312.
6. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-1124.
7. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006 Jun 15;55(3):420-426.
8. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 Dec;66(12):1560-1567. Epub 2007 Jul 27.
9. Dykman TR, Gluck OS, Murphy WA, et al. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum. 1985 Apr;28(4):361-368.
10. Bijlsma JWJ, Saag KG, Buttgereit F, da Silva JAP. Developments in glucocorticoid therapy. Rheum Dis Clin North Am. 2005 Feb;31(1):1-17, vii.
11. Lodder MC, Lems WF, Kostense PJ, et al. Bone loss due to glucocorticoids: update of a systematic review of prospective studies in rheumatoid arthritis and other diseases. Ann Rheum Dis. 2003;62(suppl 1):94.
12. Sambrook PN, Eisman JA, Yeates MG, et al. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis. 1986 Nov;45(11):950-953.
13. Verhoeven AC, Boers M. Limited bone loss due to corti-costeroids: a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol. 1997 Aug;24(8):1495-1503.
14. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis. 1986 Oct;45(10):852-7.
15. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocor-ticoids. Osteoporos Int. 2011 Mar;22(3):809-816. Epub 2011 Jan 13.
16. van Staa TP, Leukens HGM, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000 Dec;39(12):1383-9.
17. Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol. 1991 Jun;18(6):804-8.
18. Baltzan MA, Suissa S, Bauer DC, Cummings SR. Hip fractures attributable to corticosteroid use (research letters). Lancet. 1999 Apr 17;353(9161):1327.
19. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995 Jan;54(1):49-52.
20. Cappell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004 Jul;63(7):797-803.
21. Aff AK, Bergman A, Harvey JC. Steroid myopathy: clinical histologic and cytologic observations. Johns Hopkins Med J. 1968 Oct;123(4):158-173.
22. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008 Jan;47(1):72-5.
23. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum (Arthritis Care Res). 2005 Aug 15;53(4):528-535.
24. Svenson KLG, Lithell H, Hällgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med. 1987 Nov;147(11):1917-1920.
25. Boers M, Nurmohamed MT, Doelman CJ, et al. Infuence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003 Sep;62(9):842-845.
26. Garcia-Gomez C, Nolla JM, Valverde J, et al. High HDL- cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest. 2008 Sep;38(9):686-692.
27. Kuroki Y, Kaji H, Kawano S, et al. Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab. 2008;26(3):271-278. Epub 2008 May 11.
28. Pasceri V, Yeh ETH. A tale of two diseases: atherosclerosis and rheumatoid arthritis (editorial). Circulation. 1999 Nov 23;100(21):2124-2126.
29. del Rincon I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 2004 Dec;50(12):3813-3822.
30. Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2011 Jan;78(1):23-30. Epub 2010 May 14.
31. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004 Nov 16;141(10):764-770.
32. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007 Apr;56(4):1125-1133.
33. Greenberg JD, Reed G, Kremer JM, et al. Association of meth- otrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010 Feb;69(2):380-386. Epub 2009 Apr 8.
34. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011 Jun;70(6):956-960. Epub 2011 Feb 1.
35. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor ne-crosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011 Dec 7;306(21):2331-2339. Epub 2011 Nov 6.
36. Stuck AE, Minder CE, Frey FJ. Risk of infectious complica- tions in patients taking glucocorticosteroids. Rev Infect Dis. 1989 Nov-Dec;11(6):954-963.
37. Toms TE, Panoulas VF, Douglas KM, et al. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2008;10(6):R145. Epub 2008 Dec 17.
38. Daly JR, Myles AB, Bacon PA, et al. Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis. Ann Rheum Dis. 1967 Jan;26(1):18-25.
39. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. 1983 Nov;5(4):319-332.
40. Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Arch Ophthalmol. 1980 Oct;98(10):1773-1777.
41. Klein BE, Klein R, Lee KE, Danforth AG. Drug use and five-year incidence of age-related cataracts: The Beaver Dam Eye Study. Ophthalmology. 2001 Sep;108(9):1670-1674.